TandemAI has secured a $22 million Series A extension to further develop its drug discovery platform, which combines advanced AI, physics-based computational methods, and wet lab capabilities. The round included both new and existing investors.

Since its founding in October 2021, the company has raised over $80M.

With a team of more than 300 professionals, TandemAI’s AI-powered, fully integrated drug discovery engine has delivered over ten candidates that are now in—or soon to enter—clinical development. The company has also partnered with four of the world’s top ten multinational pharmaceutical companies, building a network of more than 150 global partners and clients.

“The financing is a strong vote of confidence in our progress to date and in our strategy,” said Jeff He, co-founder and CEO of TandemAI. “This funding will support AI and computational physics-based model development for multiple modalities, as well as wet lab capacity expansion to accommodate our rapidly growing client base.”

Read more: The Role of Artificial Intelligence in Drug Discovery